<DOC>
	<DOCNO>NCT00836212</DOCNO>
	<brief_summary>Background Low concentration protease inhibitor ( PIs ) nonnucleoside reverse transcriptase inhibitor ( NNRTIs ) associate increase risk virological failure . Likewise , excessive antiretroviral drug concentration increase risk toxicity . Therapeutic drug monitoring ( TDM ) may identify correct excessively high low PI and/or NNRTI concentration , thus minimize toxicity risk treatment failure . Treatment guideline recommend use TDM help optimize ARV therapy select patient , clear recommendation guide clinician decides adjust drug dos . Prospective study demonstrate relationship EFV plasma concentration neuropsychiatric symptom . Moreover , EFV metabolize mainly cytochrome P450 2B6 concentration report associated CYP2B6 516GrT genetic polymorphism . For drug EFV LPV/r , low dos one validate standard clinical use demonstrate efficacy dose-ranging study . The investigator use standardise algorithm reduce dose patient plasma EFV LPV/r concentration percentile 75 . This algorithm base Bayesian approach pharmacology unit Lausanne . The investigator hypothesize dosage individualisation feasible safe . 2.2 Study Aims The investigator aim test simplify algorithm dose reduction patient document virological efficacy , treat stable LPV/r EFV base regimen elevate plasma concentration drug . Study Design Prospective open label study eligible patient screen plasma drug concentration either EFV LPV/r percentile 75 include . After confirmation result baseline , patient offer decrease drug dosage third half accord standardise algorithm . All patient undergo HIVRNA , biochemistry validate questionnaire 3 6 month assess safety benefit strategy .</brief_summary>
	<brief_title>Adjusting Antiretroviral Therapy Dosage Using Therapeutic Drug Monitoring</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Stable regimen include either EFV LPV/r HIVRNA 40 copy since least 3 month Antiretroviral drug concentration ( EFV , LPV/r ) plasma concentration screen P75 Signed consent SHCS genetics core project Concomitant medication : Amiodarone , bepidril , flecainide , propafenone , quinidine , Astemizole , terfenadine , Dihydroergotamine , ergotamine , Midazolam , triazolam , Cisapride , Pimozide , Rifabutin Renal hepatic impairment Pregnancy wish become pregnant within next 6 month Both EFV LPV/r part antiretroviral drug regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>HIV</keyword>
	<keyword>Adjusting Antiretroviral Therapy</keyword>
	<keyword>Dosage use Therapeutic Drug Monitoring</keyword>
	<keyword>Swiss HIV Cohort Study</keyword>
	<keyword>HIV Geneva</keyword>
	<keyword>lopinavir</keyword>
	<keyword>efavirenz</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>